Skip to content
Review Open access

Microbiota-Associated Metabolites as Immunometabolic Regulators of Glomerular Inflammation: Disease-Specific Mechanisms and Therapeutic Opportunities

Oct 2026 · Journal of Inflammation Research · Vol 19 · 0 citations · 104 references
Medicine

Abstract

Background Immunoglobulin A nephropathy (IgAN), membranous nephropathy (MN), and lupus nephritis (LN) are immune-mediated glomerular diseases in which dysregulated adaptive immunity converges with innate inflammatory and filtration-barrier injury. Clinical relapse and incomplete recovery despite upstream immune control motivate investigation of additional injury modifiers. Main Body This review evaluates five microbiota-associated metabolite families—short-chain fatty acids (SCFAs), tryptophan-derived metabolites, aromatic amino acid-derived uremic solutes, trimethylamine N-oxide (TMAO), and bile acids—across three modules: immune-tolerance failure, innate inflammatory amplification, and filtration-barrier disruption. In IgAN, multi-omics data showing preserved or elevated systemic acetate with reduced glomerular free fatty acid receptor 2/3 (FFAR2/FFAR3)-associated signaling suggest impaired renal SCFA sensing, but do not establish receptor competence as the dominant target. In MN, disease-specific studies support podocyte injury mediated by complement C3a and its receptor (C3a/C3aR) and complement-associated NOD-, LRR- and pyrin domain-containing protein 3 (NLRP3)–caspase-1–gasdermin D (GSDMD) pyroptosis as related injury processes, whereas proposed SCFA–regulatory T cell (Treg)–B-cell and SCFA–inflammasome interactions remain largely hypothesis-generating; experimental Lactobacillus–indole–aryl hydrocarbon receptor (AhR) data provide preliminary evidence. In LN, microbiota-dependent tryptophan pathway perturbation and treatment-associated metabolomic changes support the kynurenine-to-tryptophan ratio as a readily measurable candidate biomarker requiring prospective validation. Across diseases, interpretation requires separating microbial production from renal retention, metabolite abundance from receptor signaling competence, and total from unbound exposure for protein-bound solutes. Conclusion Microbiota-associated metabolites constitute a plausible immunometabolic layer rather than established causal pathways in immune-mediated glomerular disease. Priorities include disease-specific longitudinal phenotyping, compartment-resolved metabolite measurement, target-engagement studies, and biomarker-embedded clinical trials before therapeutic claims are advanced.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.